TY - JOUR
T1 - microPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide
AU - Wu, Yun
AU - Zhang, Xianzhong
AU - Xiong, Zhengming
AU - Cheng, Zhen
AU - Fisher, Darrell R.
AU - Liu, Shuang
AU - Gambhir, Sanjiv S.
AU - Chen, Xiaoyuan
PY - 2005/10/1
Y1 - 2005/10/1
N2 - Integrin αvβ3 plays a critical role in tumor-induced angiogenesis and metastasis and has become a promising diagnostic indicator and therapeutic target for various solid tumors. Radiolabeled RGD peptides that are integrin specific can be used for noninvasive imaging of integrin expression level as well as for integrin-targeted radionuclide therapy. Methods: In this study we developed a tetrameric RGD peptide tracer 64Cu-DOTA-E{E[c(RGDfK)]2}2 (DOTA is 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid) for PET imaging of integrin αvβ3 expression in female athymic nude mice bearing the subcutaneous UG87MG glioma xenografts. Results: The RGD tetramer showed significantly higher integrin binding affinity than the corresponding monomeric and dimeric RGD analogs, most likely due to a polyvalency effect. The radio-labeled peptide showed rapid blood clearance (0.61 ± 0.01 %ID/g at 30 min and 0.21 ± 0.01 %ID/g at 4 h after injection, respectively [%ID/g is percentage injected dose per gram]) and predominantly renal excretion. Tumor uptake was rapid and high, and the tumor washout was slow (9.93 ± 1.05 %ID/g at 30 min after injection and 4.56 ± 0.51 %ID/g at 24 h after injection). The metabolic stability of 54Cu-DOTA-E{E[c(RGDfK)]2}2 was determined in mouse blood, urine, and liver and kidney homogenates at different times after tracer injection. The average fractions of intact tracer in these organs at 1 h were approximately 70%, 58%, 51%, and 26%, respectively. Noninvasive microPET studies showed significant tumor uptake and good contrast in the subcutaneous tumor-bearing mice, which agreed well with the biodistribution results. Integrin αvβ3 specificity was demonstrated by successful blocking of tumor uptake of 64Cu-DOTA-E{E[c(RGDfK)] 2}2 in the presence of excess c(RGDyK) at 1 h after injection. The highest absorbed radiation doses determined for the human reference adult were received by the urinary bladder wall (0.262 mGy/MBq), kidneys (0.0296 mGy/MBq), and liver (0.0242 mGy/MBq). The average effective dose resulting from a single 64Cu-DOTA-E{E[c(RGDfK)]2} 2 injection was estimated to be 0.0164 mSv/MBq. Conclusion: The high integrin and avidity and favorable biokinetics make 64Cu-DOTA- E{E[c(RGDfK)]2}2 a promising agent for peptide receptor radionuclide imaging and therapy of integrin-positive tumors.
AB - Integrin αvβ3 plays a critical role in tumor-induced angiogenesis and metastasis and has become a promising diagnostic indicator and therapeutic target for various solid tumors. Radiolabeled RGD peptides that are integrin specific can be used for noninvasive imaging of integrin expression level as well as for integrin-targeted radionuclide therapy. Methods: In this study we developed a tetrameric RGD peptide tracer 64Cu-DOTA-E{E[c(RGDfK)]2}2 (DOTA is 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid) for PET imaging of integrin αvβ3 expression in female athymic nude mice bearing the subcutaneous UG87MG glioma xenografts. Results: The RGD tetramer showed significantly higher integrin binding affinity than the corresponding monomeric and dimeric RGD analogs, most likely due to a polyvalency effect. The radio-labeled peptide showed rapid blood clearance (0.61 ± 0.01 %ID/g at 30 min and 0.21 ± 0.01 %ID/g at 4 h after injection, respectively [%ID/g is percentage injected dose per gram]) and predominantly renal excretion. Tumor uptake was rapid and high, and the tumor washout was slow (9.93 ± 1.05 %ID/g at 30 min after injection and 4.56 ± 0.51 %ID/g at 24 h after injection). The metabolic stability of 54Cu-DOTA-E{E[c(RGDfK)]2}2 was determined in mouse blood, urine, and liver and kidney homogenates at different times after tracer injection. The average fractions of intact tracer in these organs at 1 h were approximately 70%, 58%, 51%, and 26%, respectively. Noninvasive microPET studies showed significant tumor uptake and good contrast in the subcutaneous tumor-bearing mice, which agreed well with the biodistribution results. Integrin αvβ3 specificity was demonstrated by successful blocking of tumor uptake of 64Cu-DOTA-E{E[c(RGDfK)] 2}2 in the presence of excess c(RGDyK) at 1 h after injection. The highest absorbed radiation doses determined for the human reference adult were received by the urinary bladder wall (0.262 mGy/MBq), kidneys (0.0296 mGy/MBq), and liver (0.0242 mGy/MBq). The average effective dose resulting from a single 64Cu-DOTA-E{E[c(RGDfK)]2} 2 injection was estimated to be 0.0164 mSv/MBq. Conclusion: The high integrin and avidity and favorable biokinetics make 64Cu-DOTA- E{E[c(RGDfK)]2}2 a promising agent for peptide receptor radionuclide imaging and therapy of integrin-positive tumors.
KW - Cu
KW - Integrin
KW - Micro-PET
KW - Multimeric peptide
KW - RGD peptide
KW - Tumor angiogenesis
UR - http://www.scopus.com/inward/record.url?scp=27944457471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27944457471&partnerID=8YFLogxK
M3 - Article
C2 - 16204722
AN - SCOPUS:27944457471
SN - 0161-5505
VL - 46
SP - 1707
EP - 1718
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 10
ER -